Lupin Ltd
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
- Market Cap ₹ 98,970 Cr.
- Current Price ₹ 2,169
- High / Low ₹ 2,312 / 1,281
- Stock P/E 33.0
- Book Value ₹ 482
- Dividend Yield 0.37 %
- ROCE 14.1 %
- ROE 11.8 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
Cons
- Stock is trading at 4.50 times its book value
- The company has delivered a poor sales growth of 5.25% over past five years.
- Company has a low return on equity of 4.44% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE 500 BSE Healthcare BSE 100 BSE 200 BSE Dollex 200
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
7,122 | 8,939 | 9,752 | 11,344 | 12,626 | 10,081 | 11,356 | 11,026 | 11,056 | 11,772 | 11,259 | 14,666 | 15,785 | |
5,224 | 6,016 | 6,375 | 7,357 | 8,134 | 7,992 | 8,504 | 9,116 | 9,012 | 11,560 | 10,295 | 11,216 | 11,553 | |
Operating Profit | 1,898 | 2,922 | 3,377 | 3,987 | 4,492 | 2,089 | 2,853 | 1,909 | 2,044 | 211 | 964 | 3,451 | 4,232 |
OPM % | 27% | 33% | 35% | 35% | 36% | 21% | 25% | 17% | 18% | 2% | 9% | 24% | 27% |
9 | 405 | 177 | 187 | 82 | 128 | -49 | -286 | 129 | 215 | 210 | 115 | 125 | |
Interest | 33 | 21 | 5 | 24 | 29 | 33 | 35 | 53 | 41 | 73 | 98 | 56 | 56 |
Depreciation | 150 | 168 | 337 | 306 | 366 | 390 | 426 | 519 | 503 | 514 | 548 | 725 | 722 |
Profit before tax | 1,724 | 3,139 | 3,212 | 3,844 | 4,179 | 1,794 | 2,342 | 1,052 | 1,630 | -162 | 527 | 2,785 | 3,579 |
Tax % | 27% | 26% | 25% | 26% | 25% | 25% | 34% | 31% | 23% | 17% | 19% | 16% | |
1,260 | 2,324 | 2,397 | 2,831 | 3,141 | 1,345 | 1,539 | 728 | 1,259 | -189 | 425 | 2,326 | 2,997 | |
EPS in Rs | 28.16 | 51.84 | 53.34 | 62.83 | 69.56 | 29.74 | 34.01 | 16.06 | 27.74 | -4.15 | 9.35 | 51.05 | 65.77 |
Dividend Payout % | 14% | 12% | 14% | 12% | 11% | 17% | 15% | 37% | 23% | -96% | 43% | 16% |
Compounded Sales Growth | |
---|---|
10 Years: | 5% |
5 Years: | 5% |
3 Years: | 10% |
TTM: | 23% |
Compounded Profit Growth | |
---|---|
10 Years: | 0% |
5 Years: | 6% |
3 Years: | 24% |
TTM: | 153% |
Stock Price CAGR | |
---|---|
10 Years: | 4% |
5 Years: | 23% |
3 Years: | 34% |
1 Year: | 69% |
Return on Equity | |
---|---|
10 Years: | 11% |
5 Years: | 5% |
3 Years: | 4% |
Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 91 | 91 | 91 | 91 | 91 | 91 |
Reserves | 4,757 | 6,889 | 8,938 | 11,823 | 14,690 | 15,695 | 17,027 | 17,383 | 18,475 | 18,059 | 18,321 | 20,512 | 21,887 |
669 | 144 | 45 | 392 | 593 | 17 | 6 | 6 | 485 | 951 | 749 | 105 | 644 | |
1,530 | 1,675 | 1,935 | 1,931 | 2,475 | 2,879 | 2,567 | 3,201 | 2,808 | 3,212 | 3,523 | 4,215 | 3,849 | |
Total Liabilities | 7,046 | 8,799 | 11,008 | 14,236 | 17,848 | 18,681 | 19,690 | 20,680 | 21,859 | 22,313 | 22,684 | 24,923 | 26,471 |
2,014 | 2,179 | 2,036 | 2,345 | 3,013 | 3,341 | 3,373 | 3,514 | 3,639 | 3,690 | 4,022 | 4,113 | 4,142 | |
CWIP | 240 | 267 | 490 | 624 | 481 | 1,171 | 1,199 | 822 | 951 | 947 | 927 | 446 | 436 |
Investments | 688 | 1,164 | 3,444 | 3,741 | 6,914 | 5,363 | 7,388 | 7,456 | 9,563 | 9,511 | 9,974 | 11,581 | 12,374 |
4,104 | 5,189 | 5,038 | 7,526 | 7,441 | 8,806 | 7,730 | 8,888 | 7,706 | 8,165 | 7,761 | 8,783 | 9,519 | |
Total Assets | 7,046 | 8,799 | 11,008 | 14,236 | 17,848 | 18,681 | 19,690 | 20,680 | 21,859 | 22,313 | 22,684 | 24,923 | 26,471 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1,008 | 1,528 | 2,852 | 917 | 4,352 | 209 | 3,111 | 2,219 | 1,570 | 151 | 1,794 | 2,504 | |
-372 | -447 | -1,178 | -2,629 | -1,941 | 725 | -2,865 | -740 | -2,508 | -372 | -1,269 | -1,599 | |
-635 | -844 | -221 | 17 | -160 | -987 | -295 | -368 | -53 | 102 | -498 | -867 | |
Net Cash Flow | 1 | 237 | 1,452 | -1,696 | 2,252 | -52 | -50 | 1,112 | -991 | -118 | 27 | 38 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 96 | 117 | 94 | 146 | 113 | 179 | 120 | 120 | 105 | 84 | 87 | 96 |
Inventory Days | 193 | 174 | 211 | 214 | 232 | 229 | 216 | 216 | 236 | 260 | 230 | 216 |
Days Payable | 126 | 124 | 126 | 126 | 161 | 150 | 118 | 136 | 104 | 110 | 119 | 148 |
Cash Conversion Cycle | 163 | 166 | 179 | 234 | 184 | 258 | 218 | 199 | 237 | 234 | 197 | 163 |
Working Capital Days | 123 | 138 | 116 | 181 | 144 | 219 | 171 | 154 | 158 | 151 | 132 | 117 |
ROCE % | 34% | 50% | 40% | 36% | 30% | 11% | 16% | 10% | 9% | -1% | 3% | 14% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 19 Dec
-
Rumour verification - Regulation 30(11)
18 Dec - Lupin receives FDA approval for HIV tablets.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
13 Dec - Lupin acquires anti-diabetes trademarks from Boehringer Ingelheim.
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 13 Dec
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 9 Dec
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Jan 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Jan 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
May 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Jan 2021TranscriptNotesPPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptPPT
-
Jun 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Jan 2020TranscriptNotesPPT
-
Nov 2019TranscriptPPT
-
Nov 2019Transcript PPT
-
Aug 2019TranscriptNotesPPT
-
May 2019TranscriptNotesPPT
-
Feb 2019Transcript PPT
-
Jan 2019TranscriptNotesPPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
Jun 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
Feb 2018TranscriptNotesPPT
-
Jan 2018TranscriptNotesPPT
-
Nov 2017Transcript PPT
-
Sep 2017TranscriptNotesPPT
-
Aug 2017TranscriptNotesPPT
-
May 2017TranscriptNotesPPT
-
Feb 2017TranscriptNotesPPT
-
Jan 2017TranscriptNotesPPT
-
Nov 2016TranscriptNotesPPT
-
Jun 2016TranscriptPPT
Products
Co. is engaged in developing and marketing generic formulations, biotechnology products, and APIs globally. Co. has a significant presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, and Central Nervous system, among other segments, and is a global leader in e Anti-TB and Cephalosporins segments. [1]